Get our Free Patent Expiration Newsletter

Serving hundreds of leading biopharmaceutical companies globally:

Chubb
Express Scripts
Queensland Health
Farmers Insurance
Healthtrust
Daiichi Sankyo

Generated: July 22, 2019

DrugPatentWatch Database Preview

Details for Patent: 8,470,347

Try a free trialSee Plans and Pricing

« Back to Dashboard

Which drugs does patent 8,470,347 protect, and when does it expire?

Patent 8,470,347 protects KALETRA and NORVIR and is included in two NDAs.

Protection for KALETRA has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has thirteen patent family members in eleven countries.

Summary for Patent: 8,470,347
Title:Self-emulsifying active substance formulation and use of this formulation
Abstract: The present invention relates to self-emulsifying formulations based on an active ingredient component and a formulation base with a lipid component and with a binder component and to the use of this formulation as dosage form in the life science sector. The invention also describes a process for producing self-emulsifying formulations by mixing the formulation components to form a plastic mixture and, where appropriate, to manufacture the formulations as dosage form advantageously by use of melt extrusion. The formulations spontaneously form emulsions in water or aqueous media.
Inventor(s): Berndl; Gunther (Herxheim, DE), Breitenbach; Jorg (Mannheim, DE), Heger; Robert (Heidelberg, DE), Stadler; Michael (Neulu.beta.heim, DE), Wilke; Peter (Ludwigshafen, DE), Rosenberg; Jorg (Ellerstadt, DE)
Assignee: AbbVie Deutschland GmbH and Co KG (Wiesbaden, DE)
Application Number:10/296,451
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 8,470,347
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 8,470,347
Patent Claim Types:
see list of patent claims
Composition; Formulation; Compound; Dosage form;

Drugs Protected by US Patent 8,470,347

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-002 Nov 9, 2007 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie KALETRA lopinavir; ritonavir TABLET;ORAL 021906-001 Oct 28, 2005 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Abbvie NORVIR ritonavir TABLET;ORAL 022417-001 Feb 10, 2010 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 8,470,347

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Germany100 26 698May 30, 2000
PCT Information
PCT FiledMay 29, 2001PCT Application Number:PCT/EP01/06116
PCT Publication Date:December 06, 2001PCT Publication Number: WO01/91727

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Mallinckrodt
Colorcon
US Army
Cantor Fitzgerald
McKinsey

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.